Under the terms of the agreement, Voyager will receive an upfront payment of $15 million and could potentially earn up to $305 million in milestone payments and royalties associated with the development, regulatory, and commercial progress of the licensed capsid.
Alfred W. Sandrock, Jr., M.D., Ph.D., CEO of Voyager Therapeutics, highlighted the significance of the partnership, stating, “Novartis is a global leader in gene therapy, and we view their continued selection of our IV-delivered, blood-brain barrier-penetrant capsids as strong validation of our TRACER capsid discovery platform.” The partnership between Voyager and Novartis now encompasses five gene therapy programs, including targets for Huntington’s disease, spinal muscular atrophy, and three other undisclosed indications.
TRACER™ Capsid Discovery Platform
Voyager’s TRACER™ platform is designed to facilitate the discovery of novel adeno-associated virus (AAV) capsids using an RNA-based screening approach. This platform has shown promise in preclinical studies, where intravenous delivery of TRACER-generated capsids demonstrated broad transduction across central nervous system regions and cell types. The TRACER platform’s capability to cross the blood-brain barrier effectively positions Voyager’s capsids for various gene therapy applications targeting neurological diseases.
About Voyager Therapeutics
Voyager Therapeutics, Inc. is committed to leveraging human genetics to develop treatments and potential cures for neurological diseases. The company’s pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), and Parkinson’s disease, among others. Voyager’s innovative TRACER™ platform has enabled the development of novel capsids designed for high brain penetration, enhancing the delivery of genetic medicines via intravenous administration.
Voyager collaborates with prominent industry partners such as Alexion, AstraZeneca Rare Disease, Novartis, Neurocrine Biosciences, and Sangamo Therapeutics to advance its gene therapy programs.
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
AAV Gene Therapy Revolutionizes Treatment for LCA1, Improving Vision Significantly
Innovative AAV Gene Therapy Dramatically Restores Vision in LCA1 Researchers have made a significant breakthrough in treating Leber congenital amaurosis type 1 (LCA1), a severe inherited retinal disease that causes early childhood blindness, by using an innovative...
Cellular Origins & 3P Innovation Partner to Streamline Cell and Gene Therapy Manufacturing
Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), has partnered with 3P innovation, an engineering company and supplier of automated fill-finish equipment, to integrate 3P...
BridgeBio ends development of gene therapy for adrenal gland disorder
BridgeBio said Tuesday night it won’t move forward with a gene therapy for a group of genetic disorders that impair adrenal glands and cause disruptions in producing cortisol. The California biotech made the decision because Phase 1/2 data were “not yet...
Gene Therapy for Inherited Deafness Approaches a Threshold
A hearing test for a newborn baby is routine. And if it reveals a hearing problem, the choice that is presented to those hoping to improve the baby’s hearing is also routine. There are usually two options: a cochlear implant or a hearing aid. But thanks to the efforts...
Related Services
AAV Packaging Services
READ MORE
Off-the-Shelf AAV Products
READ MORE
